At present, the vaccine authorized in children aged 5 years and older is the BNT162b2 messenger RNA COVID-19 vaccine. Unlike adults, there is limited data available in the pediatric age describing adverse events after vaccine. We report a case of adenomesenteritis in a young girl following the first dose of vaccine.
Adenomesenteritis following sars-cov-2 vaccination in children. a case report and review of the literature / Bloise, S.; Marcellino, A.; Martucci, V.; Sanseviero, M.; Testa, A.; Del Giudice, E.; Spatuzzo, M.; Sermoneta, D.; Ventriglia, F.; Lubrano, R.. - In: CHILDREN. - ISSN 2227-9067. - 9:7(2022), pp. 1-10. [10.3390/children9070993]
Adenomesenteritis following sars-cov-2 vaccination in children. a case report and review of the literature
Bloise S.
;Marcellino A.;Testa A.;Sermoneta D.;Ventriglia F.;Lubrano R.
2022
Abstract
At present, the vaccine authorized in children aged 5 years and older is the BNT162b2 messenger RNA COVID-19 vaccine. Unlike adults, there is limited data available in the pediatric age describing adverse events after vaccine. We report a case of adenomesenteritis in a young girl following the first dose of vaccine.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bloise_Adenomesenteritis-following-vaccination_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
861.91 kB
Formato
Adobe PDF
|
861.91 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
